TX-MARY-KAY-INC
14.12.2022 23:42:39 CET | Business Wire | Press release
Mary Kay Inc., a global advocate for corporate social responsibility, today released a report detailing progress on Enriching Lives Today for a Sustainable Tomorrow (ELTFAST), the brand’s global sustainability program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005001/en/
Enriching Lives Today for a Sustainable Tomorrow extends Mary Kay's vision to 2030 and beyond. (Credit: Mary Kay Inc.)
“We’re proud of the progress we’ve made on our sustainability journey so far, and we are inspired to see how our actions today will address global challenges for future generations,” said Deborah Gibbins, Chief Operating Officer at Mary Kay Inc. “Mary Kay has operations in nearly 35 countries—we consider that an accomplishment and a responsibility. Enriching Lives Today for a Sustainable Tomorrow is our roadmap for supporting our business strategy, reducing our environmental impact, and supporting communities where we operate.”
Enriching Lives Today for a Sustainable Tomorrow extends Mary Kay’s vision to 2030 and beyond. It builds a picture of what good “looks like” for Mary Kay, Independent Beauty Consultants, customers and—most importantly—the planet. Enriching Lives Today for a Sustainable Tomorrow was developed with Mary Kay’s key stakeholders and is aligned with the United Nations’ Sustainable Development Goals, making Mary Kay a key part of a global coalition to ensure a better future.
The 2020 – 2022 full report can be viewed here. An executive summary of the report is available here.
Since the launch of ELTFAST in 2020, Mary Kay has made significant progress toward its goals despite the many challenges presented by the COVID-19 epidemic. The 2022 report details its efforts since 2020—the beginning of its Decade of Action—and serves as a reaffirmation of the company’s drive to deliver sustainable change.
Business Excellence
- Focusing on nurturing its company culture, Mary Kay garnered 13 employer / great place to work awards and was ranked #8 on list of “The Companies Employees Don’t Want to Leave,” published by Resume.io.
- Released gender diversity data in leadership: executive team is 54% female, managers and above are 59% female, with 62% of the total workforce being female.
- In 2021, scored 75% employee engagement, a 6% increase over the 2019 full engagement survey (This is 10% over the global average for employee engagement).
- 38 company awards in business excellence, social impact, and sustainability.
-
Deloitte named Mary Kay Inc. one of the 2022 U.S. Best Managed Companies.
Product Stewardship
- Achieved Forest Stewardship Council (FSC) certification (U.S.A only). The FSC certification ensures products come from responsibly managed forests providing environmental, social and economic benefits.
- 12% of our indirect suppliers are women, minority or veteran-owned (U.S.A. only).
- Achieved palm oil–88% certified and palm kernel–72% certified.
- Held inaugural Sustainability-Focused Supplier Summit at global headquarters.
- Named 2022 Silver Champion for Supplier Diversity & Inclusion.
-
Nominated and approved member of the steering committee for SPICE (Sustainable Packaging Initiative for CosmEtics).
Responsible Manufacturing
- Supported The Arbor Day Foundation on three global reforestation projects in Brazil, Madagascar, and the United States.
- Continued additional water usage analysis with plans to install new water flow meters.
- Supported The Nature Conservancy’s Global Reefs program through 12 unique impact programs.
- Joined the UN Global Compact’s Ocean Stewardship Coalition.
- Richard R. Rogers Manufacturing/R&D facility (R3), announced it passed its OSHA VPP Star Re-Certification with zero findings and recommendations.
- Received OSHA Star Re-Certification Credentials.
Women’s Empowerment
- Published “Piloting SDG Localization at the Village Level: A Women-focused Poverty Reduction and Sustainable Development Project in Yunnan Province, China.” Impact Report (Phase 1: 2017-2021).
- Completed The Women’s Empowerment Principles Gender Gap Analysis Tool as part of our participation in the UN Global Compact Target Gender Equality Accelerator.
- Advanced women’s leadership in the fishing industry in Mexico through eight projects implemented by The Nature Conservancy.
- Powered the global launch of a free Entrepreneurship Program in six languages, developed by International Trade Centre SheTrades Initiative.
- Awarded 14 STEAM grants to young women around the world pursuing dreams in STEAM-related industries.
- Joined the UN Global Compact Target Gender Equality Program to deepen implementation of the Women’s Empowerment Principles.
- Submitted survey on the implementation of commitments across the Generation Equality Action Coalitions; findings reflected in UN Women’s Generation Equality Accountability Report 2022.
Social Impact
- Since 2008, Pink Changing Lives has impacted more than six million women and their families by partnering with over 3,250 organizations and donating over $17 million. In 2022, the cause empowerment program supported over 20 NGOs around the world.
- Mary Kay and the Mary Kay Ash Foundation grants supported the development and launch of a “GBV Guidance for Development Programs” and its rollout in 10 countries of intervention as well as the establishment of a Community of Practice convening 240 members across 16 countries to date.
- Mary Kay and the Mary Kay Ash Foundation grants helped the UN Trust Fund change the lives of 54,822 women and girl survivors of violence through 157 GBV projects in 68 countries across five regions including women and girls living with disabilities, internally displaced or refugee women and girls, and Indigenous women and girls.
- Donated more than $1.3 million to global organizations helping to enrich women’s lives.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
